Trastuzumab, an anti-HER2 monoclonal antibody, was approved as an adjuvant treatment for HER2+ breast cancer by the National Institute of Clinical Excellence (NICE) in August 2006. This evidence concerns the gene ERBB2 and breast carcinoma.